Cargando…
Antibodies against type I interferon: detection and association with severe clinical outcome in COVID‐19 patients
OBJECTIVES: Impairment of type I interferon (IFN‐I) immunity has been reported in critically ill COVID‐19 patients. This defect can be explained in a subset of patients by the presence of circulating autoantibodies (auto‐Abs) against IFN‐I. We set out to improve the detection and the quantification...
Autores principales: | Goncalves, David, Mezidi, Mehdi, Bastard, Paul, Perret, Magali, Saker, Kahina, Fabien, Nicole, Pescarmona, Rémi, Lombard, Christine, Walzer, Thierry, Casanova, Jean‐Laurent, Belot, Alexandre, Richard, Jean‐Christophe, Trouillet‐Assant, Sophie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370568/ https://www.ncbi.nlm.nih.gov/pubmed/34429968 http://dx.doi.org/10.1002/cti2.1327 |
Ejemplares similares
-
Type‐I Interferon assessment in 45 minutes using the FilmArray(®) PCR platform in SARS‐CoV‐2 and other viral infections
por: Mommert, Marine, et al.
Publicado: (2021) -
Type I IFN immunoprofiling in COVID-19 patients
por: Trouillet-Assant, Sophie, et al.
Publicado: (2020) -
Evaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients
por: Pescarmona, Rémi, et al.
Publicado: (2021) -
A third vaccine dose equalises the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Lyon, France, December 2021 to March 2022
por: Guibert, Nicolas, et al.
Publicado: (2023) -
A Case of Type 2 Hypersensitivity to Rasburicase Diagnosed with a Natural Killer Cell Activation Assay
por: Viel, Sébastien, et al.
Publicado: (2018)